Project Grant R21AG091142
Award Date
9/30/24
Completion Date
8/31/26
Dollars Obligated
$432K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
East Lansing, MI 48824, USA
Similar Awards
This Project Grant award, with a total funding amount of $130,302.00, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award, with an effective date of July 15, 2025 and an ultimate completion date of March 31, 2030, supports research at New York University (NYU) to investigate the molecular and functional impacts of pathological tau accumulation in basal forebrain cholinergic neurons and its consequences for Alzheimer's...
This $999,822 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Aeton Therapeutics Inc. supports the development of an anti-tau monoclonal antibody treatment for Alzheimer's disease. The key objectives are to: Evaluate the effectiveness of Aeton's lead candidate, AT-01, in treating neural cells and organoids in vitro compared to another anti-tau antibody, HJ8.7. Determine the efficacy and safety of AT-01 versus HJ8.7 in a mouse model of tauopathy, while...
The National Institute on Aging (NIA) awarded a $7,249,563 Project Grant under the Aging Research federal grant program (CFDA 93.866) to the Regents of the University of California, San Francisco (UCSF). This 3-year award, starting on Aug 1, 2023, will support research to characterize the structural properties and variability of tau protein aggregation in different brain cell types and at different disease stages of Alzheimer's and related dementias (ADRD). The project aims to develop new...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Jillion Therapeutics Inc. aims to identify small molecule compounds that can bind to and modify the biological behavior of tau protein, which is implicated in Alzheimer's disease and other neurodegenerative "tauopathies". The $496,373 award, spanning September 2024 to August 2025, will utilize the company's DNA-encoded library (DEL) drug discovery platform to screen a large chemical...
This Project Grant award of $1,698,335.00 from the National Institute on Aging (part of the Aging Research program, CFDA 93.866) supports the development and preclinical testing of self-adjuvanting peptide nanofiber (PNF) vaccines targeting amyloid-beta and tau proteins for Alzheimer's disease and frontotemporal dementia. The grant aims to: 1) assess the toxicity and seeding capacity of PNFs bearing these epitopes, 2) characterize the antibody responses to AB and tau PNF vaccines, and 3) develop...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research at Virginia Commonwealth University (VCU) to investigate the effect of the trans-synaptic spread of pathogenic tau protein in the hippocampus and its impact on vulnerable neuron subtypes in Alzheimer's disease (AD). The $408,638 award, effective from August 1, 2024 to July 31, 2026, will involve the use of adeno-associated viral vector transfection, immunofluorescence, and...
This $519,750 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a 2-year research study by the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco. The study aims to explore the underlying molecular mechanisms by which reducing levels of the tau protein can prevent or diminish excitation/inhibition imbalance and network hyperexcitability in the brain. This imbalance has been observed in various...
The University of North Carolina at Chapel Hill (UNC-CH) received a $424,095 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to develop a CRISPR/Cas13 gene therapy targeting the tau protein for the treatment of Alzheimer's disease and other tauopathies. The project aims to identify and validate optimal guide RNAs to deplete specific tau isoforms in neurons, and evaluate the therapeutic potential of this approach in preclinical Alzheimer's disease mouse...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $1,592,854 to the University of Illinois to conduct research on tau protein conformation and its role in Alzheimer's disease and related dementias. The key focus areas include: Defining the effects of tau post-translational modifications on tau function and pathology. This will evaluate how modifications like phosphorylation, acetylation, and cross-linking impact the exposure of tau's regulatory...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $437,250 to the University of California, San Diego (UCSD) to develop new tools for imaging the tau protein and its phase transitions in living cells. The research aims to map and measure tau in its soluble, liquid-liquid phase separation, and liquid-solid phase separation forms, which is a critical limitation in the field. The project will leverage a peptide-based probe and...